2,4-Dichloropyrimidine is a critical intermediate in the synthesis of Pazopanib, an oral angiogenesis inhibitor used in the treatment of advanced renal cell carcinoma and soft tissue sarcoma. As a key building block in the formulation of this oncology drug, the quality and purity of 2,4-Dichloropyrimidine directly influence the efficacy and safety of the final API (Active Pharmaceutical Ingredient).